ArticleScientific reports2025
The use of autologous platelet-rich plasma in embryo culture to obtain high-quality embryos.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Use of platelet lysate from estrus heifer forFrontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Transferring high-quality embryos is crucial for in vitro fertilization success, as they lead to better clinical pregnancy and live birth outcomes. Researchers have investigated adding supplements to culture media to enhance embryo quality because culture conditions greatly affect embryo quality and development. This study assessed whether adding autologous platelet-rich plasma containing growth factors and cytokines to the culture media could produce more usable and high-grade embryos. This retrospective study analyzed 175 in vitro fertilization cycles from 123 women with poor embryo development or no usable embryos in previous cycles. 5% platelet-rich plasma solution was added to the cleavage-stage culture medium, and embryos were incubated for 48 h. Embryo development rates, stage-specific usable embryos, and high-quality embryo proportions were measured. Cytokine analysis was performed to compare the platelet-rich plasma samples from patients with high- and low-quality embryos. Adding autologous platelet-rich plasma significantly improved embryo development outcomes, with higher usable embryo rates compared to untreated groups. Platelet-rich plasma enhanced outcomes at the blastocyst stage and improved high-quality embryo rates at the morula and blastocyst stages. Both POSEIDON groups II and IV showed significantly better usable embryo ratios with platelet-rich plasma. Significant differences in cytokine expression levels were observed between platelet-rich plasma samples from patients with high- and low-quality embryo samples, with notable variations in Flt-3 ligand, interleukin-23, monocyte chemoattractant protein-3, and urokinase plasminogen activator receptor. The limitations of this study are retrospective design without a placebo control group and its small sample size. Nevertheless, our findings are valuable for patients with poor prognoses, showing improved embryo development outcomes. This offers opportunities for older patients with multiple failed in vitro fertilization attempts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.